The Cathedral and the Bazaar: Why Ayurveda Research Remains Invisible to Global Science

How PubMed and Scopus Became the Gatekeepers of Medical Knowledge—And What Ayurveda Must Do to Gain Entry

Dr Aakash Kembhavi

The Stark Reality: Modern medicine produces more research in two weeks than Ayurveda has indexed in its entire recorded history on Scopus. This isn’t just a numbers game—it’s a structural problem that reveals how scientific legitimacy is manufactured, maintained, and monetized in the 21st century.

Part I: The Architecture of Academic Power

The Birth of a Monopoly

The story of how PubMed and Scopus became global reference standards is less about scientific merit and more about strategic positioning at critical moments in history.

PubMed’s Government-Backed Genesis

In 1964, the U.S. National Library of Medicine launched MEDLARS (Medical Literature Analysis and Retrieval System), transitioning from the print-based Index Medicus to computerized indexing. By 1971, MEDLINE went online—but only through specialized telecommunications requiring institutional access and command-line expertise. This wasn’t democratization; it was controlled distribution to elite research institutions.

The revolutionary moment came in 1997 when PubMed became freely accessible via the internet. This timing was masterful: the web was exploding, institutional funding for digital infrastructure was surging, and the NIH positioned PubMed as a “public good”—while maintaining absolute curatorial control over what counted as legitimate biomedical research.

Critical Insight: PubMed’s “free access” model is a Trojan horse. While searching is free, the infrastructure determining what gets indexed remains tightly controlled by the U.S. National Library of Medicine’s Literature Selection Technical Review Committee. This committee—composed primarily of Western-trained physicians and researchers—defines “biomedicine and health, broadly defined to encompass those areas of the life sciences, behavioral sciences, chemical sciences, and bioengineering needed by health professionals.”

Notice what’s absent: traditional medicine systems, unless they conform to Western research paradigms.

Scopus: The Corporate Alternative

Elsevier launched Scopus in 2004 as a commercial competitor to Web of Science, but with a crucial difference: it claimed “source-neutral” curation through an independent Content Selection Advisory Board (CSAB). This board, comprised of “approximately 20 scientists and 10 librarians from all corners of the world,” reviews thousands of journal applications annually.

The numbers tell the story: Every year, thousands of titles are suggested for Scopus inclusion, but only 33% meet technical criteria, and of those, only 50% are accepted by the CSAB. Result: Roughly 16.5% acceptance rate—more selective than Harvard.

Critical Insight: Elsevier’s “independence” claim deserves scrutiny. As both a major publisher AND the owner of Scopus, Elsevier has structural conflicts of interest despite the CSAB. The 2009 establishment of CSAB was a response to criticism, not a founding principle. Meanwhile, Scopus subscription fees run into six figures for institutions—making it “free to search” but expensive to maintain access.

Part II: The Machinery of Legitimacy

How Indexing Became the Currency of Academic Worth

The genius of PubMed and Scopus wasn’t just organizing medical literature—it was creating a self-reinforcing system where:

  1. Universities require publication in indexed journals for hiring and promotion
  2. Funding agencies prioritize grants to researchers with indexed publication records
  3. Journal rankings (Impact Factor, CiteScore) derive from these databases
  4. National research assessments use these metrics to allocate billions in funding

This creates a circular logic: journals need indexing to attract quality submissions, but need quality submissions to get indexed. Breaking into this circle from the outside is nearly impossible without institutional backing.

The Infrastructure Trap

Both PubMed and Scopus didn’t just emerge—they were built on decades of institutional investment:

PubMed’s Foundation:

  • Backed by the U.S. National Institutes of Health (annual budget: ~$47 billion)
  • Connected to PubMed Central (free full-text repository since 2000)
  • Linked to ClinicalTrials.gov (launched 2000, now with 300,000+ trials)
  • Integrated with MeSH (Medical Subject Headings)—a controlled vocabulary developed over 60+ years
  • Supported by NCBI (National Center for Biotechnology Information, established 1988)

Scopus’s Foundation:

  • Backed by Elsevier (annual revenue: ~$3 billion)
  • Two years of development with 21 research institutions and 300+ researchers/librarians
  • Integration with SciVal, Mendeley, and other Elsevier products
  • 7,000+ publisher relationships
  • Daily content updates from global sources

Critical Question: How can traditional medicine systems compete with this level of infrastructure investment without equivalent institutional and financial backing?

Part III: The Selection Criteria—Where Ayurveda Fails

PubMed’s MEDLINE Selection Process

Journals are evaluated by the Literature Selection Technical Review Committee on a 0-5 point scale. Only those scoring 3.75+ are selected—roughly 25% acceptance rate. Criteria include:

  1. Scope and Coverage: Must contribute to “biomedicine and health” as defined by NLM
  2. Quality of Content: Peer review, originality, scientific rigor using Western methodology
  3. Editorial Quality: International editorial boards, English abstracts minimum
  4. Production Quality: Regular publication schedule, proper formatting
  5. Audience: Must serve health professionals and researchers globally

Where Ayurveda Falls Short:

  • Definitional Bias: NLM’s scope emphasizes molecular biology, biochemistry, and bioengineering—paradigms often misaligned with Ayurvedic principles
  • Methodology: RCTs (Randomized Controlled Trials) are gold standard; Ayurveda’s individualized, multi-component treatments don’t fit this mold
  • Language Hierarchy: Even with English abstracts, journals from non-English contexts face implicit bias
  • Citation Networks: MEDLINE judges “importance” partly by citation frequency from already-indexed journals—a closed loop

Scopus’s CSAB Evaluation

Five categories determine acceptance:

  1. Journal Policy: Peer review, ethics statements, conflicts of interest policies
  2. Content: Scientific quality, clarity, relevance to Scopus audience
  3. Journal Standing: Reputation, author diversity, citation patterns
  4. Publishing Regularity: Consistent publication schedule over 2+ years
  5. Online Availability: Accessible website, English interface, DOI assignment

Where Ayurveda Falls Short:

  • Citation Poverty: Only ~5,700 Ayurveda articles in Scopus total. New journals can’t demonstrate citation impact without existing indexed presence
  • Journal Metrics: Scopus judges quality partly through existing journal metrics (h-index, CiteScore)—metrics new journals can’t have
  • Network Effects: 2.4 billion cited references in Scopus come overwhelmingly from Western journals citing other Western journals
  • Technical Requirements: Many Ayurveda journals lack DOIs, don’t use JATS XML, or have inconsistent archiving

Critical Analysis: The criteria appear neutral but encode specific epistemological assumptions. “Scientific rigor” means Western scientific method. “Global relevance” means relevance to Western research agendas. “Quality control” means conformity to Western publishing standards.

Part IV: The Trial Registry Imperative

Why Clinical Trial Registration Became Non-Negotiable

In 2000, the U.S. established ClinicalTrials.gov following scandals about unpublished negative trial results. By 2005, WHO established the International Clinical Trials Registry Platform (ICTRP), declaring: “The registration of all interventional trials is a scientific, ethical and moral responsibility.”

The WHO ICTRP Requirements:

Primary registries must:

  1. Have government backing with national/regional mandate
  2. Accept prospective registration before first patient enrollment
  3. Collect and display the WHO Trial Registration Data Set (20 mandatory fields)
  4. Maintain publicly accessible audit trails of all changes
  5. Submit data in English to WHO Central Repository
  6. Meet ICMJE requirements for journal publication consideration

Ayurveda’s Trial Registry Problem:

There is no comprehensive, WHO-recognized trial registry for Ayurveda studies. The CTRI (Clinical Trials Registry - India) exists but:

  • Covers all Indian clinical research, not Ayurveda-specific
  • Many Ayurveda researchers don’t register trials
  • No enforcement mechanism for registration
  • Registration numbers rarely cited in Ayurveda journal articles

Critical Insight: Without trial registration, Ayurveda research is systematically excluded from systematic reviews, meta-analyses, and evidence synthesis—the very tools Western medicine uses to establish clinical guidelines.

Part V: The Fragmentation Crisis

Ayurveda’s Database Diaspora

Your data reveals the problem starkly:

Existing Ayurveda Databases:

  • AYUSH Research Portal (Government of India)
  • DHARA (Digital Helpline for Ayurveda Research Articles)
  • ARD (Ayurvedic Research Database)
  • Annotated Bibliography of Indian Medicine

The Problem: These databases remain:

  • Unmerged despite repeated recommendations
  • Incompletely indexed (44 out of 105 Ayurveda journals indexed nowhere)
  • Unsearchable through standard academic interfaces
  • Invisible to international researchers

Critical Analysis: This fragmentation isn’t accidental—it’s symptomatic of:

  1. Institutional rivalry between Indian government departments
  2. Lack of centralized funding for database maintenance
  3. Absence of international standards compliance
  4. No accountability for database quality or completeness

When researchers worldwide search for evidence on traditional medicine, they use PubMed. If Ayurveda isn’t there, it doesn’t exist to them.

Part VI: The Visibility Paradox

Why 5,700 Articles Is Both Too Many and Too Few

The Number: Scopus contains approximately 5,700 Ayurveda articles—accumulated over decades.

The Context: Modern medicine publishes roughly 2,000-2,500 articles daily in PubMed alone.

The Math: Ayurveda’s entire Scopus presence equals 2-3 weeks of modern medical publishing.

The Paradox: This makes Ayurveda simultaneously:

  • Too small to register as significant in global research metrics
  • Too dispersed across 105 journals (many with 1-2 articles/year)
  • Too inconsistent in quality and methodology to aggregate reliably

Critical Question: Is the problem too little Ayurveda research, or too little indexed, findable, citable Ayurveda research?

The Citation Bankruptcy

PubMed’s Network Effects:

  • Average MEDLINE article receives citations from other MEDLINE articles
  • Citations determine journal metrics (Impact Factor)
  • Journal metrics determine indexing decisions
  • Indexing determines citation opportunities

Ayurveda’s Position:

  • Most Ayurveda journals have Impact Factors below 1.0 or none at all
  • Low citation rates exclude journals from PubMed consideration
  • Exclusion from PubMed prevents citation accumulation
  • Result: Permanent exclusion from the citation economy

Part VII: What Ayurveda Must Do—A Roadmap

Immediate Actions (0-2 Years)

1. Database Unification

Stop the excuses. Merge AYUSH Portal, DHARA, and ARD into a single, authoritative platform:

  • One search interface for all Ayurveda research
  • English metadata for international accessibility
  • DOI assignment for every article retroactively
  • JATS XML conversion for modern interoperability
  • WHO TRDS compliance for trial data

Estimated Cost: $2-3 million USD for development and 5 years operation Current Reality: Indian AYUSH Ministry budget exceeds $600 million annually but lacks coordinated digital infrastructure investment

2. Establish WHO-Recognized Ayurveda Trial Registry

Not another database—a PRIMARY REGISTRY meeting WHO ICTRP standards:

  • Government mandate letter from India (and ideally other Ayurveda-practicing nations)
  • Prospective trial registration before patient enrollment
  • 20 mandatory WHO TRDS fields in standardized format
  • Public audit trails and data quality SOPs
  • Integration with ICTRP Search Portal

Key Challenge: This requires government commitment and international coordination, not just institutional initiative.

3. Create Flagship Journals with Rigorous Standards

Rather than 105 small journals, consolidate around 10-15 premier outlets:

  • Full open access with CC-BY licenses
  • Mandatory ORCID for all authors
  • Preprint archiving on recognized servers
  • Transparent peer review with reviewer names
  • COPE (Committee on Publication Ethics) membership
  • Rigorous plagiarism screening
  • English as primary language with translation support

Model: Look at Journal of Ayurveda and Integrative Medicine (already indexed in PubMed and Scopus)—but replicate this success 10 times over with specialized journals.

Medium-Term Actions (2-5 Years)

4. Methodological Innovation, Not Imitation

This is crucial: Ayurveda cannot and should not simply adopt Western RCT methodology wholesale. Instead:

Develop Ayurveda-Specific Research Standards:

  • Validated outcome measures for prakriti (constitution) assessment
  • Standardized protocols for individualized treatment reporting
  • Metrics for multi-component interventions
  • Long-term observational study designs appropriate to Ayurvedic practice
  • Integrative biomarker approaches combining traditional and modern diagnostics

Then: Publish these standards in both Ayurveda journals AND high-impact Western journals (Nature Medicine, JAMA, BMJ) to educate the global community

Critical Insight: The goal isn’t to abandon Ayurvedic principles to fit Western boxes—it’s to demonstrate scientific rigor within Ayurvedic paradigms so convincingly that Western institutions must adapt their evaluation criteria.

5. Citation Network Building

Strategic Cross-Citation:

  • Ayurveda researchers must cite relevant PubMed-indexed articles
  • When publishing in Western journals, cite Ayurveda literature
  • Create review articles synthesizing Ayurveda and modern research
  • Publish in hybrid journals bridging traditional and modern medicine

Key Journals to Target:

  • Journal of Ethnopharmacology (IF: 4.8)
  • Evidence-Based Complementary and Alternative Medicine (Indexed in PubMed)
  • Phytomedicine (IF: 6.7)
  • Journal of Alternative and Complementary Medicine (Indexed in PubMed)

6. International Research Collaborations

The Harvard-AIIMS Model:

  • Partner premier Indian Ayurveda institutions with top Western universities
  • Joint grant applications to NIH, Wellcome Trust, ERC
  • Co-authored publications in high-impact journals
  • Visiting scholar exchange programs

Critical Success Factor: These must be genuine collaborations where Ayurveda principles inform study design, not token traditional medicine components grafted onto Western protocols.

Long-Term Actions (5-10 Years)

7. Create Alternative Metrics That Matter

While working toward PubMed/Scopus inclusion, build parallel legitimacy:

Patient Outcome Registries:

  • Large-scale, prospective, observational databases of Ayurveda treatment outcomes
  • Real-world evidence of effectiveness
  • Published transparently online
  • Peer-reviewed analysis

Economic Impact Studies:

  • Cost-effectiveness compared to conventional treatment
  • Healthcare system burden reduction
  • Published in health economics journals

Systematic Reviews Using Ayurveda Databases:

  • Conduct rigorous systematic reviews of Ayurveda literature
  • Register reviews with PROSPERO (international register for systematic reviews)
  • Publish in both Ayurveda and Western journals
  • Demonstrate that Ayurveda evidence exists—even if not in PubMed

8. Policy Advocacy

Target:

  • WHO Traditional Medicine Strategy implementation
  • NIH Office of Complementary and Integrative Health funding
  • Wellcome Trust global health initiatives
  • National research funding agencies in India, EU, and Asia

Message: “Traditional medicine systems serve billions globally but remain invisible in research databases due to structural barriers, not lack of evidence. Reform indexing criteria to include epistemologically diverse approaches meeting appropriate rigor standards.”

9. The Nuclear Option: Create a Scopus Competitor

Radical but feasible: India, China, and other traditional medicine-practicing nations collectively fund a Global Traditional Medicine Research Database that:

  • Matches Scopus technical capabilities
  • Uses culturally appropriate quality criteria alongside Western standards
  • Provides free API access for researchers globally
  • Gets government recognition in member countries for academic promotion

Cost: ~$50-100 million for 10 years Precedent: China already built CNKI (China National Knowledge Infrastructure)—a massive Chinese-language database now integrated with many international platforms

Political Reality: This requires geopolitical will. But if 3+ billion people use traditional medicine, why should their research be judged solely by Western gatekeepers?

Part VIII: The Uncomfortable Truths

Why This Is So Hard

1. The Epistemological Divide Is Real

Ayurveda’s framework—tridosha theory, prakriti constitution, rasa-guna-vipaka properties—doesn’t easily translate to reductionist biomedicine. Pretending this divide doesn’t exist helps no one.

Critical Choice: Either demonstrate that Ayurvedic concepts have measurable biological correlates (prakriti → genomics/metabolomics), or argue persuasively that not all medical knowledge must reduce to molecular mechanisms to be valid and useful.

2. Quality Control Is Genuinely Problematic

The honest assessment: Many Ayurveda journals DO have problems:

  • Inadequate peer review
  • Conflicts of interest
  • Weak methodology
  • Overstated conclusions
  • Plagiarism issues

The Solution: This doesn’t justify exclusion—it justifies raising standards. But Ayurveda institutions must lead this quality improvement, not wait for external pressure.

3. The Language Barrier Is Non-Negotiable

Like it or not, English dominates international research. Sanskrit and regional Indian language research will never achieve global visibility without translation.

Hard Truth: This isn’t cultural imperialism—it’s network effects. Chinese researchers publish in English. Japanese researchers publish in English. German researchers publish in English. Indian researchers must too if they want global recognition.

4. Money Matters

PubMed and Scopus represent billions in institutional investment over decades. Ayurveda institutions cannot compete financially. Therefore:

Strategic Approach: Focus resources ruthlessly on achievable goals:

  • 10 flagship journals, not 105 mediocre ones
  • 1 unified database, not 5 fragmented ones
  • 1 WHO trial registry, not informal registration
  • Targeted high-impact research collaborations, not scattered projects

Part IX: The Power Analysis

Who Benefits from Ayurveda’s Exclusion?

Western Pharmaceutical Industry:

  • Biopiracy of traditional knowledge without attribution
  • Absence of prior art documentation facilitates patent claims
  • Traditional remedies remain “alternative” rather than “evidence-based”

Western Academic Institutions:

  • Maintain monopoly on “scientific” medicine definition
  • Control research funding flows
  • Preserve journal publishing revenue streams

Publishing Oligopoly:

  • Elsevier, Springer, Wiley control 70%+ of medical journals
  • Scopus indexing drives journal subscriptions (profitable)
  • Traditional medicine journals often open access (less profitable)

Critical Question: Is the exclusion of traditional medicine from global research databases a feature or a bug of the current system?

Who Suffers from Ayurveda’s Invisibility?

3+ Billion Traditional Medicine Users:

  • Evidence base for their healthcare remains hidden
  • Safety and efficacy data not systematically evaluated
  • Integration with modern medicine hampered

Global Health:

  • Potential treatments and preventive approaches undiscovered
  • Antimicrobial resistance crisis could benefit from traditional antimicrobials
  • Chronic disease management often better served by holistic approaches

Scientific Progress:

  • Ayurveda’s 3,000+ year empirical dataset largely unexplored
  • Plant medicine biodiversity underutilized
  • Alternative paradigms for health and disease unconsidered

Conclusion: The Choice Ahead

Ayurveda faces a choice:

Path A: Assimilation

  • Conform completely to Western research standards
  • Accept reductionist methodology
  • Publish primarily in Western journals
  • Gradually achieve indexing through conformity

Outcome: Recognition, but at cost of epistemological integrity. Ayurveda becomes “complementary” rather than an independent system.

Path B: Parallel Institution Building

  • Create alternative research infrastructure
  • Maintain epistemological distinctiveness
  • Build evidence base using appropriate methodologies
  • Demand reform of global indexing standards

Outcome: Autonomy, but continued exclusion from mainstream research discourse. Risk of irrelevance.

Path C: Strategic Hybrid (Recommended)

  • Meet technical standards (DOIs, JATS XML, English metadata, trial registration)
  • Develop Ayurveda-specific research methods validated through collaboration
  • Publish strategically in both Ayurveda and indexed journals
  • Build parallel infrastructure while working toward indexing inclusion
  • Use policy advocacy to reform evaluation criteria

Outcome: Gradual recognition while preserving epistemological integrity. Long timeline but sustainable.

The Bottom Line

PubMed and Scopus became global reference standards through:

  1. Strategic timing (digitization era)
  2. Institutional backing (government/corporate investment)
  3. Infrastructure development (decades of investment)
  4. Network effects (citations begetting citations)
  5. Standard setting (controlling the definition of quality)

Ayurveda cannot replicate this history, but it can learn from it:

Required Actions:

  • Unified, high-quality database infrastructure ($5-10M investment)
  • WHO-recognized trial registry (government mandate required)
  • 10 flagship journals meeting international technical standards
  • Strategic international collaborations and cross-citation
  • Methodological innovation demonstrating rigor within Ayurvedic paradigms
  • Policy advocacy for reform of indexing criteria

Timeline: 10-15 years minimum for significant progress

Political Will Required: High—this needs coordinated action from Indian government, international Ayurveda institutions, and global traditional medicine advocates

Alternative: Continue fragmentation and invisibility while Western institutions cherry-pick Ayurvedic knowledge without attribution or proper validation.

The choice is clear. The question is whether Ayurveda’s institutional leaders have the vision, coordination, and persistence to make it happen.

The uncomfortable truth: Academic indexing systems aren’t neutral arbiters of quality—they’re power structures that perpetuate specific epistemological frameworks. Ayurveda’s exclusion isn’t accidental; it’s structural. Change requires not just meeting standards, but challenging the assumptions those standards encode.

The cathedral was built to exclude the bazaar. Now the bazaar must either build its own cathedral or storm the gates.

Which will it be?

Share your thoughts in the comments below.